Skip to content

Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.

Risk-Targeted Behavioral Activation: a Novel Approach to the Management of Treatment-Resistant Depression.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06729580
Enrollment
118
Registered
2024-12-11
Start date
2022-01-05
Completion date
2023-10-30
Last updated
2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment Resistant Depression (TRD)

Keywords

treatment resistant depression, catastrophic thinking, perceived injustice, behavioural activation

Brief summary

Depression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is the most common diagnosis made for individuals seeking treatment for depression. Although a wide range of treatments have been developed for the treatment of MDD, a significant proportion of patients fail to respond. This study examined the effectiveness of a 10-week behavioural activation intervention for individuals with treatment-resistant depression.

Detailed description

Objective: The purpose of the present study was to examine the acceptability and impact of a standardized 10-week risk-targeted behavioral activation (RTBA) intervention as an augmentation strategy in the clinical management of treatment-resistant depression (TRD). Methods: The study sample consisted of 118 individuals with TRD, who were currently absent from work and referred to an occupational rehabilitation service. The RTBA intervention was a 10-week standardized program consisting of weekly visits with a trained clinician. The objectives of treatment included symptom reduction, resumption of important life activities (including return to work) and improvement in quality of life. Measures of depression, perceived injustice, and catastrophic thinking were completed pre-, mid- and post-treatment.

Interventions

10-week standardized behavioural activation program.

Sponsors

McGill University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* A diagnosis of Major Depressive Disorder * The date of diagnosis of MDD preceded referral by at least 12 months * At least one previous prescription of an antidepressant failed to yield therapeutic response * Currently taking an antidepressant * A PHQ9 score in the moderate to severe range of depression at the time of enrolment

Exclusion criteria

\- Participating in another psychotherapeutic intervention.

Design outcomes

Primary

MeasureTime frameDescription
Depression symptom severity.baseline/immediately after the interventionThe Patient Health Questionnaire (PHQ9) was used to assess depressive symptom severity. PHQ-9 scores can range from 0 to 27 with higher scores indicating more severe depressive symptoms.

Secondary

MeasureTime frameDescription
Catastrophic thinkingbaseline/immediately after the intervention.The Symptom Catastrophizing Scale (SCS) was used to assess catastrophic appraisals of depressive symptoms. Scores on the SCS range from 0 to 14 where higher scores reflect a higher degree of catastrophic thinking.
Perceived Injusticebaseline/immediately after the intervention.The Injustice Experience Questionnaire - Short Form (IEQ-SF) was used to assess injustice appraisals. Scores on the IEQ-SF range from 0 to 10 where higher scores reflect a greater sense of injustice.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026